Kadderum

Eltrombopag, the active ingredient in Kadderum, is a thrombopoietin receptor agonist presented as an oral formulation for oral use. It stimulates platelet production and is used in patients with chronic immune thrombocytopenia and aplastic anemia.

GNH USA supplies Kadderum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Eltrombopag acts on the thrombopoietin pathway to increase platelet counts in hematologic disorders.

- Chronic immune thrombocytopenia (ITP): helps raise and maintain platelet levels, reducing bleeding risk. - Aplastic anemia: supports bone‑marrow recovery by promoting megakaryocyte proliferation and platelet formation.

Eltrombopag may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Diarrhea: generally self‑limiting. - Fatigue: reported in some patients. - Upper respiratory tract infection: mild symptoms.

Serious or Rare Side Effects: - Hepatic toxicity: elevated liver enzymes or hepatitis. - Thromboembolic events: arterial or venous clot formation. - Cataracts: visual disturbances requiring ophthalmologic evaluation. - Severe neutropenia: marked reduction in neutrophil count. - Severe infections: opportunistic or systemic infections.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

- Liver function monitoring: check ALT/AST levels periodically. - Blood count surveillance: track platelet, neutrophil, and hemoglobin levels. - Hypertension caution: avoid use in uncontrolled high blood pressure. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Concomitant chelators: avoid iron, calcium, magnesium supplements within 2 hours of dosing. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Eltrombopag's absorption and metabolism can be altered by several co‑administered agents.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce oral absorption. - Iron supplements: significantly decrease bioavailability. - Calcium‑containing products: interfere with drug uptake.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - CYP3A4 inducers (e.g., rifampicin): may lower drug exposure. - Other hepatotoxic agents: add risk of liver injury. - Warfarin: potential for altered anticoagulant effect; monitor INR. - Immunosuppressants: may compound bone‑marrow suppression.